uniQure Preclinical Data Huntington’s Show Safety, Widespread Long-Term HTT Lowering

  uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that three manuscripts on preclinical data from its gene therapy candidate AMT-130 in Huntington’s disease have been accepted for publication, in the journals Science Translational Medicine, Brain Science, and Brain Communications. The publications show the safety and efficacy of AMT-130 in the deep brain structures of a large animal model and outline a promising novel efficacy biomarker for AMT-130.

https://www.globenewswire.com/news-release/2021/04/08/2206570/0/en/uniQure-Announces-Publications-of-Preclinical-Data-for-AMT-130-in-Huntington-s-Disease-Showing-Safety-of-Administration-in-NHPs-and-Widespread-Long-Term-HTT-Lowering-in-the-Brain.html